Stryker (NYSE:SYK) Upgraded to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Stryker (NYSE:SYK) from a hold rating to a buy rating in a research report sent to investors on Saturday morning.

A number of other research firms have also recently commented on SYK. BTIG Research lowered their target price on Stryker from $371.00 to $358.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Truist Financial upped their price target on Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a research note on Friday, July 31st. Wells Fargo & Company decreased their price objective on Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a report on Friday, May 1st. Leerink Partners lowered their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Price Performance

Shares of NYSE SYK opened at $338.85 on Friday. Stryker has a 1 year low of $281.00 and a 1 year high of $396.86. The stock has a market capitalization of $129.97 billion, a P/E ratio of 35.11, a P/E/G ratio of 2.16 and a beta of 0.76. The company’s 50-day moving average is $320.11 and its 200 day moving average is $334.13. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. Stryker’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period last year, the business posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, sell-side analysts expect that Stryker will post 15.02 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. Stryker’s payout ratio is presently 36.48%.

Insiders Place Their Bets

In other news, VP M Kathryn Fink sold 3,500 shares of Stryker stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the completion of the transaction, the vice president owned 177 shares of the company’s stock, valued at $50,170.65. The trade was a 95.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Stryker

Institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Stryker by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock worth $11,917,396,000 after buying an additional 133,892 shares in the last quarter. State Street Corp increased its position in shares of Stryker by 2.1% during the fourth quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock valued at $5,374,731,000 after acquiring an additional 311,507 shares in the last quarter. Geode Capital Management LLC raised its holdings in Stryker by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock worth $2,636,238,000 after acquiring an additional 69,851 shares during the last quarter. Wellington Management Group LLP raised its holdings in Stryker by 22.6% in the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock worth $2,282,192,000 after acquiring an additional 1,198,665 shares during the last quarter. Finally, Norges Bank bought a new position in Stryker in the 4th quarter valued at approximately $1,822,272,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.